BrainsWay Announces Draft Coverage Policy from Highmark® for Accelerated Deep TMS™

New draft policy from Highmark Blue Cross Blue Shield extends to both adolescent and adult depression patients New draft policy from Highmark Blue Cross Blue Shield extends to both adolescent and adult depression patients

GlobeNewsWire • Jan 21, 2026

BrainsWay Announces FDA Approval of Neurolief's Proliv™Rx Neuromodulation System for Major Depressive Disorder (MDD)

BrainsWay's strategic investment in Neurolief paved the way for the first and only FDA approved at-home neuromodulation device with Class III Premarket Approval labeling for MDD patients who failed one or more prior antidepressants BrainsWay's strategic investment in Neurolief paved the way for the first and only FDA approved at-home neuromodulation device with Class III Premarket Approval labeling for MDD patients who failed one or more prior antidepressants

GlobeNewsWire • Jan 12, 2026

BrainsWay Announces First Coverage Policy for Accelerated Deep TMS™

New Premera Blue Cross Blue Shield® policy extends to both adolescent and adult depression patients New Premera Blue Cross Blue Shield® policy extends to both adolescent and adult depression patients

GlobeNewsWire • Jan 7, 2026

BWAY Shares Gain on Optum Expanding Deep TMS Coverage for Teens

BrainsWay stock rises after Optum expands Deep TMS coverage for adolescents, boosting reimbursement visibility.

Zacks Investment Research • Dec 23, 2025

BrainsWay Reports Expansion of Adolescent Depression Coverage Applicable to Deep TMS™

Optum Behavioral Health, a Health Services Company with Over 48 Million Covered Lives, Joins Growing List of Insurers Now Covering Deep TMS Depression Therapy for Adolescents Aged 15 and Older Optum Behavioral Health, a Health Services Company with Over 48 Million Covered Lives, Joins Growing List of Insurers Now Covering Deep TMS Depression Therapy for Adolescents Aged 15 and Older

GlobeNewsWire • Dec 22, 2025

BrainsWay Ltd. (BWAY) Analyst/Investor Day Transcript

BrainsWay Ltd. (BWAY) Analyst/Investor Day Transcript

Seeking Alpha • Dec 1, 2025

BrainsWay to Host Virtual Analyst & Investor Day to Discuss the Company's Growth Strategy and Deep TMS™ Treatment December 1, 2025

BURLINGTON, Mass. and JERUSALEM, Nov. 25, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive brain stimulation technologies, today announced that it will host a virtual Analyst & Investor Day on Monday, December 1, 2025 at 10:00 AM ET, during which company management will highlight various aspects of BrainsWay's growth strategy. The event will feature Owen Scott Muir, MD, DFAACAP (Co-Founder, Chief Medical Officer, Radial), who will discuss the significant unmet need for various conditions and his clinical experience utilizing Deep TMS™, and Michael Gershenzon, CEO of Stella MSO, a management services organization servicing more than 20 mental health clinics across the U.S. and Israel, who will discuss his experience working with BrainsWay on BrainsWay's strategic minority-stake investment in Stella. To register, click here.

GlobeNewsWire • Nov 25, 2025

BrainsWay Launches First Clinical Trial of Deep TMS 360™ System for Alcohol Use Disorder

Multicenter, randomized, controlled study will evaluate Company's next-generation multichannel TMS technology in reducing heavy drinking and cravings Multicenter, randomized, controlled study will evaluate Company's next-generation multichannel TMS technology in reducing heavy drinking and cravings

GlobeNewsWire • Nov 17, 2025

BrainsWay Receives FDA Clearance of Deep TMS™ as Adjunct Therapy for Major Depressive Disorder (MDD) in Adolescents Aged 15 to 21

Deep TMS™ becomes first and only TMS device cleared in treatment of patients aged 15 to 86 suffering from depression Deep TMS™ becomes first and only TMS device cleared in treatment of patients aged 15 to 86 suffering from depression

GlobeNewsWire • Nov 13, 2025

BrainsWay Ltd. (BWAY) Q3 2025 Earnings Call Transcript

BrainsWay Ltd. ( BWAY ) Q3 2025 Earnings Call November 11, 2025 8:30 AM EST Company Participants Hadar Levy - Chief Executive Officer Ido Marom - Chief Financial Officer Conference Call Participants Brian Ritchie - Lifesci Advisors, LLC Jeffrey Cohen - Ladenburg Thalmann & Co. Inc., Research Division Carl Byrnes - Northland Capital Markets, Research Division Raghuram Selvaraju - H.C.

Seeking Alpha • Nov 11, 2025